Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ACC-001 (vanutide cridificar)
ACC-001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 3 μg ACC-001 / QS-21 50 μg IM dose 1 | EXPERIMENTAL | 3 μg ACC-001 / QS-21 50 μg IM |
| 10 μg ACC-001 / QS-21 50 μg IM dose 2 | EXPERIMENTAL | 10 μg ACC-001 / QS-21 50 μg IM |
| Placebo - Phosphate buffered saline (PBS) IM dose | NO_INTERVENTION | Placebo - Phosphate buffered saline (PBS) IM |
| Name | Type | Description |
|---|---|---|
| ACC-001 (vanutide cridificar) | BIOLOGICAL | Comparisons of 2 different doses of ACC-001 or placebo for 24 months |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to 89 * Mini-Mental Status Exam score of 18-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiver able to...
Top 20 of 30 competitors
ACC-001 is an investigational monoclonal antibody developed by Johnson & Johnson for Alzheimer's Disease. It was studied in a Phase 2 clinical trial in subjects with mild to moderate Alzheimer's Disease. It is not approved for any indication and remains in clinical development.
ACC-001 is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 2 study of ACC-001 in Alzheimer's Disease.
ACC-001 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
ACC-001 has been studied in one completed Phase 2 trial, NCT01284387, titled Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease. The trial enrolled 126 participants in the United States and was randomized, double-blind, and no-treatment controlled.
Yes, ACC-001 is also known as vanutide cridificar. Both names refer to the same investigational monoclonal antibody developed by Johnson & Johnson for Alzheimer's Disease.